The Natural Polypeptides as Significant Elastase Inhibitors

Shabir Ahmad\textsuperscript{1,2}, Muhammad Saleem\textsuperscript{1*,} Naheed Riaz\textsuperscript{1}, Yong Sup Lee\textsuperscript{3}, Reem Diri\textsuperscript{4}, Ahmad Noor\textsuperscript{4}, Diena Almasri\textsuperscript{4}, Alaa Bagalagel\textsuperscript{4} and Mahmoud Fahmi Elsebai\textsuperscript{5,6}\textsuperscript{*}

\textsuperscript{1} Department of Chemistry, Baghdad-ul-Jadeed Campus, The Islamia University of Bahawalpur, Bahawalpur, Pakistan, \textsuperscript{2} Department of Chemistry, Post-Graduate College, Bahawalpur, Pakistan, \textsuperscript{3} Department of Life and Nanopharmaceutical Sciences & Medicinal Chemistry Laboratory, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South Korea, \textsuperscript{4} Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia, \textsuperscript{5} Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia, \textsuperscript{6} Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Human neutrophil elastase (HNE) is a major cause of the destruction of tissues in cases of several different chronic and inflammatory diseases. Overexpression of the elastase enzyme plays a significant role in the pathogenesis of various diseases including chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, rheumatoid arthritis, the rare disease cyclic hematopoiesis (or cyclic neutropenia), infections, sepsis, cystic fibrosis, myocardial ischemia/reperfusion injury and asthma, inflammation, and atherosclerosis. Human neutrophil elastase is secreted by human neutrophils due to different stimuli. Medicine-based inhibition of the over-activation of neutrophils or production and activity of elastase have been suggested to mend inflammatory diseases. Although the development of new elastase inhibitors is an essential strategy for treating the different inflammatory diseases, it has been a challenge to specifically target the activity of elastase because of its overlapping functions with those of other serine proteases. This review article highlights the reported natural polypeptides as potential inhibitors of elastase enzyme. The mechanism of action, structural features, and activity of the polypeptides have also been correlated wherever they were available.

Keywords: elastases, natural products, polypeptides, anti-inflammatory, marine natural products

INTRODUCTION

The regulation of immune response and controlling inflammation are the customary roles of human neutrophil cells. Along with other serine proteases, human neutrophils secrete HNE, which is a 29 kDa serine protease of the chymotrypsin family. HNE contains a charge relay system consisting of the catalytic triad of aspartate, serine, and histidine residues that are dispersed throughout the polypeptide. Neutrophil elastase is closely related to other cytotoxic immune serine proteases, such as cathepsin G, proteinase 3, and the granzymes (Thomas et al., 2014; Hilhorst et al., 2015). It has a broad substrate specificity. For example, the intracellular HNE breaks down pathogenic proteins, whereas the extracellular HNE helps in the migration of neutrophils to the inflammation sites through the degradation of the extracellular matrix proteins. HNE has the ability to degrade the...
body's own cellular matrix as well as proteins that are foreign to the body. HNE also conducts proteolysis and plays a significant role in several biological processes. Despite the positive attributes, overproduction and uncontrolled functioning of elastase may produce devastating effects and cause serious damage to the host (Crocetti et al., 2019).

Under normal conditions, the activity of HNE is controlled by endogenous inhibitors including secretory leukocyte proteinase inhibitor, α1-antitrypsin (α1-AT), α2- macroglobulin, and elafin, but excessive and uncontrolled activity of HNE can cause serious damage to the tissues resulting in COPD, cyclic hematopoiesis, pulmonary emphysema (the loss of lungs elasticity), rheumatoid arthritis, pancreatitis, cystic fibrosis, psoriasis and bullous dermatoses, asthma, and systemic inflammatory response syndrome (Horwitz et al., 1999; Elsebai et al., 2012; Crocetti et al., 2019; Thulborn et al., 2019). HNE also localizes to Neutrophil extracellular traps (NETs) through its high DNA affinity, an unusual property for serine proteases. Studies have established that NETs are associated with increased lung injury and mucus clogging in cystic fibrosis (Thomas et al., 2014; Khan et al., 2019). A wide variety of studies have highlighted the proteolytic activity of elastase in causing structural changes, such as higher mean intercapillary and alveolar enlargement both in mice and in rats. Several changes resulted from elastase administration such as disorganized elastin, degradation of proteoglycans, and abnormal collagen remodeling. Regarding the dose and number of elastase challenges, many scientific groups demonstrated that mice subjected to five elastase administrations with a 1-week interval between them developed not only a more severe alveolar destruction, but also systemic manifestations, such as diaphragmatic dysfunction, weight loss, pulmonary arterial hypertension, and exercise intolerance (De et al., 2016; Crocetti et al., 2019; Giacalone et al., 2020). Thus, inhibition of elastase by chemical drugs has also been suggested as a way to recover from different inflammatory diseases. Unfortunately, the present anti-inflammatory drugs are only alleviating the symptoms of these diseases but not the progression of the disease (Barnes and Stockley, 2005). Sivelestat is the only approved drug working as a selective HNE inhibitor. However, clinical trials revealed an insufficient therapeutic efficacy of the drug in human severe lung injury and respiratory inflammation (Zeijer et al., 2004). Additionally, sivelestat has the risks of organ toxicity and poor pharmacokinetics (Tsai et al., 2015; Giacalone et al., 2020). The problem in developing new elastase inhibitors is the interference function of elastase with other proteases.

The recognition of neutrophil elastase as a promising target in chronic inflammatory diseases has increased (Wagner et al., 2016; Dittrich et al., 2018; Giacalone et al., 2020). This is why we have chosen to shed light on natural polypeptides as potential inhibitors of elastase, and lists the relevant structures and activity relationship for the high active polypeptides-based inhibitors. Additionally, this review article offers information about the chemical structures and structural features of these compounds, structural elucidation including their absolute configuration, and structure-activity relationship.

Generally, natural peptides have poor absorption, distribution, metabolism, and excretion (ADME) properties with rapid clearance, sometimes low solubility, low permeability, and a short half-life. Strategies have been developed to improve peptide drugability through prolonging half-life, reducing renal clearance and proteolysis, and enhancing permeability. In silico, in vitro, and in vivo tools are available to evaluate ADME characteristics of natural peptides, and structural functional modification strategies are ongoing to improve peptide developability. Clear understanding and improving the physicochemical properties that govern peptide conformation is critical in assessing the impact on potency and ADME properties (e.g., stability, permeability, and PK) (Di, 2014).

Porcine pancreatic elastase (PPE) has the advantage of being inexpensive and is able to induce features of lung damage and panacinar emphysema.

**ANTI-ELASTASE POLYPEPTIDES OF BACTERIAL ORIGIN**

**Polypeptides From the Cyanobacteria Lyngbya spp.**

The genus _Lyngbya_ (marine cyanobacteria) is a prolific producer of peptides. The depsipeptide _lyngbyastatin 4_ (1) (**Figure 1**) is produced by the marine cyanobacterium _Lyngbya confervoides_ from the Florida Atlantic coast. The planar structure of _lyngbyastatin 4_ (1) was confirmed by NMR measurements, whereas the absolute stereochemistry was corroborated through chiral HPLC analysis of its hydrolyzed moieties. Compound 1 contains an unusual aa homotyrosine and a residue of 3-amino-6-hydroxy-2-piperidone (Ahp). It selectively inhibited _PPE in vitro_ with an IC₅₀ = 0.03 μM (Matthew et al., 2007). In another study, compound 1 potently inhibited PPE and HNE (IC₅₀ 0.041 ± 2.0 and 0.049 ± 1.4 μM, respectively) (Salvador et al., 2013). This compound showed no cytotoxicity to various cancerous cell lines. _Lyngbyastatin 4_ (1) is an analogue of several marine cyanobacterial compounds such as dolastatin 13, and it was revealed that many of the dolastatins are originated from cyanobacteria (Matthew et al., 2007).

Three more _lyngbyastatins, 5-7_ (2-4), and a cyclodepsipeptide somamide B (5) were discovered in the culture of cyanobacteria, _Lyngbya_ spp., (South Florida). The chemical structures of compounds 2-5 (**Figure 1**) were established due to NMR measurements, while the absolute configuration was established based on Marfeq's analysis of the acid hydrolysis. All these compounds 2-5 selectively and potently inhibited PPE.
The potent PPE inhibitory activities of compounds 2-5 were observed with similar IC50 values of 0.0032 (2), 0.0033 (3), 0.0083 (4), and 0.0095 (5) µM (Taori et al., 2007). In another study, compound 4 potently inhibited PPE and HNE with IC50 values of 0.003 and 0.0023 µM, respectively (Salvador et al., 2013). Compound 4 potently and specifically inhibited elastase where it was tested at a single concentration of 10 µM against a group of 68 proteases and it showed preferential and complete inhibition for the serine proteases elastase, proteinase K, and chymotrypsin (Salvador et al., 2013). As part of the mode of action of these peptides, Salvador et al. studied their selective inhibitory activity against elastase through co-crystallization of the most potent inhibitor, lyngbyastatin 7 (4), with PPE. The co-crystal complex of the PPE −lyngbyastatin 7 was solved at 1.55 Å resolution. The study revealed that these compounds act as substrate mimics, where the Abu moiety (2-amino-2-butenoic acid) and the N-terminal residues occupy subsites S1 to S4. Besides a non-bonded interaction of ethylidene moiety of Abu unit with Ser203, it also binds to Gly201 and Ser222 through H-bonding, and an indirect H-bond with Thr44 through a molecule of water (Salvador et al., 2013). Due to the selectivity and potency of lyngbyastatin 7 (4) in inhibiting PPE, it was considered as a promising lead and subjected to further developmental studies (Luo and Luesch, 2020).

Marine cyanobacteria continue to furnish polypeptides, as *Lyngbya semiplena* (Tumon Bay, Guam) provided three cyclodepsipeptides, lyngbyastatins 8-10 (6-8) (Figure 1). These isolates were characterized by MS, ESIMS fragmentation, NMR, and chemical decomposition, and were found to have similar structural features to lyngbyastatin 4 (1). Compounds 6-8 inhibited PPE with IC50 0.123, 0.21, and 0.12 µM, respectively (Kwan et al., 2009). Structure-activity relationship of compounds 6-8 was compared to that of lyngbyastatin 7 (4), and it was proposed that differences in structure of the side chain contributed to their potency reduction. In addition, the occurrence of hydrophobic moieties in the pendant chain is supposed to establish electrostatic and H-bonding interactions with the enzyme. However, the presence of a bromide atom didn’t significantly impact the activity of 8 compared to those of 6 and 7 (Kwan et al., 2009).

The two depsipeptide analogues of dolastatin 13, bouillomides A (9) and B (10) (Figure 1), were characterized and found in the extract of the cyanobacterium *Lyngbya*.
bouillonii. Both compounds selectively inhibited PPE with the same IC\textsubscript{50} value of 1.9 µM (Rubio et al., 2010). Taori et al. (2008) identified a cyclodepsipeptide named kempopeptin A (11) (Figure 1) which was isolated from *Lyngbya* spp. This compound exhibited an IC\textsubscript{50} against PPE of 0.3 µM. Peptide 11 selectively inhibited elastase activity by binding through the aa residue between Ahp and Thr (Taori et al., 2008).

As a conclusion, in compounds 1-11, a 6-unit cyclic core, having Ahp and a pendant side chain, is very rigid, due to H bonding between Ahp and Val, which makes the hydrolysis of the inhibitor difficult. The Abu moiety adjacent to the Ahp unit makes the elastase more susceptible to the lyngbyastatin series (Kwan et al., 2009) due to H-bonding.

*Lyngbya confervoides* (southeastern Florida) produced more cyclodepsipeptides, tiglicamides A-C (12-14), and largamides A-C (15-17) (Figure 2). The unique feature of these compounds is that they contain an unusual moiety, viz. tiglic acid. Compounds 12-14 moderately inhibited PPE in vitro with IC\textsubscript{50} between 2.1 and 7.3 µM (Matthew et al., 2009b). Authors further reported 2-3 times lower activity, against PPE or other mammalian elastases, of compounds 12-14 as compared to lyngbyastatins 5-7 (2-4) (Matthew et al., 2007; Taori et al., 2007). The investigators also identified the corresponding largamide methyl esters of compounds 12-14, which were supposed to be the isolation artifacts, however, these ester derivatives helped to establish SAR, and it was proposed that carboxylic acid moiety is not responsible for the activity of elastase inhibition, since methylation at that position did not affect the activity (Matthew et al., 2009b). The largamides A-C (15-17) also have medium inhibition of PPE activity in vitro with IC\textsubscript{50} between 0.5 and 1.4 µM but no activity against chymotrypsin and trypsin up to 50 µM. It was suggested that the carboxylic acid functionality of the glutamic acid moiety in largamides A-C (15-17) play a role in elastase inhibition. They showed moderate in vitro activity against PPE in a dose-dependent manner with IC\textsubscript{50} 1.4, 0.5, and 1.2 µM, respectively but remain inactive against the tested cancerous cell lines IMR-32, HT29, and U2OS (Matthew et al., 2009a).

**Polypeptides From the Cyanobacterium *Symploca* sp.**

Salvador et al. isolated the symplostatins 5-10 (18-23) (Figure 3) from the red cyanobacterium *Symploca* sp. (Cetti Bay, Guam). Compounds 21-23 potently inhibited PPE with IC\textsubscript{50} values 0.043, 0.037, and 0.044 µM, respectively, and also potently inhibited HNE with IC\textsubscript{50} values of 0.041, 0.028, and 0.021 µM, respectively, and compounds 18-20 gave higher IC\textsubscript{50} values from 0.121 to 0.195 µM. Through SAR study and X-ray co-crystal structural analyses, it was analyzed that compounds 21-23, containing N-Me-Tyr, have a higher potential than the N-Me-Phe analogues 18-20 in elastase inhibition. It is further observed that Ile to Val substitution and pendant side chain have no effect on the activity. Compounds 21-23 and lyngbyastatins 4 (1) and 7 (4) exhibited more potential in inhibiting the PPE than the standard drug sivelestat, whereas compounds 18-20 exhibited higher IC\textsubscript{50} values comparable to the activity of sivelestat (Salvador et al., 2013).

To study the cytoprotective effects of 18 against elastase-induced antiproliferation and apoptosis, investigators utilized the BEAS-2B (bronchial epithelial cell line), an SV-40. Compound 18 prevented the antiproliferative effect of elastase on MTT assay against BEAS-2B cell with an IC\textsubscript{50} 0.077 µM at 24 h (Salvador et al., 2013). A striking feature of compound 18 is that it showed a comparable potential to sivelestat and didn’t show any toxicity on the bronchial cells. In conclusion, it was

**FIGURE 2 |** Structures of tiglicamides A-C (12-14) and largamides A-C (15-17) from *Lyngbya confervoides*, all are cyclic depsipeptides with unusual tiglic acid and Abu moieties and without Ahp unit.
stated that symplostatin 5 (18) alleviated chronic pulmonary diseases. Therefore, compound 18 offers a remarkable window to establish the molecular basis and biomarkers for elastase inhibitors that can aid in the creation of second generation inhibitors (Salvador et al., 2013).

Polypeptide From the Cyanobacterium Stigonema sp.

Another depsipeptide, stigonemapeptin (24) (Figure 4), was produced by Stigonema sp. (a freshwater cyanobacterium from northern Wisconsin). The characteristic feature of 24 was that it contains an Ahp residue and the modified aa Abu and N-formylated proline residue. Compound 24 showed in vitro PPE inhibition with IC₅₀ 0.3 µM (Kang et al., 2012).

Polypeptides From the Cyanobacteria Oscillatoria spp.

The cyclic depsipeptide oscillapeptin (25) (Figure 5) was obtained from another cyanobacterium, Oscillatoria agardhii (NIES-204). Compound 25 inhibited elastase enzyme activity with IC₅₀ 2.5 µM. This depsipeptide 25 contains Ahp, an acyl group, and 7 aa or their derivatives and hence it is related to dolastatin 13 and micropeptins. The unusual feature of oscillapeptin (25) is that it has two homotyrosine units and N, O-dimethyltyrosine moiety, which is rare in natural peptides. This unique feature of similar peptides with a variety of aa compositions offers interest to biochemists to study their biosynthetic pathway (Shin et al., 1995). During other investigations, Oscillatoria agardhii in three different cultured conditions produced oscillapeptins A, B, D, and E (26-29).
These compounds inhibited elastase with IC₅₀ 2.5, 4.2, 2.6, and 2.7 µM, respectively (Itou et al., 1999).

The cyclic depsipeptides oscillapeptin G (30) and oscillapeptilides 97-A (31) and -B (32) (Figure 5) were produced by the toxic strains of Oscillatoria agardhii, having the elastase inhibition property with IC₅₀ 1.0, 6.9, and 3.9 µM, respectively (Fujii et al., 2000). The tricyclic peptide microviridin I (33) (Figure 6) was obtained from the non-toxic strain of Oscillatoria agardhii. This compound showed inhibitory activity towards elastase release with IC₅₀ 1.9 µM (Fujii et al., 2000).

**Polypeptides From the Cyanobacteria Nostoc spp.**

Another cyanobacterium, *Nostoc minutum* (NIES-26), inhabiting fresh water, has been reported to produce microviridin-type peptides, which were identified as microviridins G (34) and H (35) (Figure 6). Both compounds potently inhibited elastase activity with IC₅₀ 1.0 and 1.7 µM, respectively (Murakami et al., 1997). Although investigators did not comment on the structural features and level of activity of 34 and 35, this may be because both the...
compounds are highly active, however, 34 is more active than 35 which could be attributed to additional cyclization in the form of lactone in compound 34, that results in slightly increased hydrophobicity.

Nostopeptins A (36) and B (37) (Figure 7) were produced by the cyanobacterium Nostoc Minutum (NIES-26). These compounds were characterized as cyclic depsipeptides-containing Ahp but not Abu unit. Both the compounds
inhibited elastase with IC$_{50}$ 1.3 and 1.2 µM, respectively (Okino et al., 1997).

From the cyanobacterium Nostoc insulare (Nostocales), eight new cyanopeptolins named insulapeptolides A–H (38-45) (Figure 8) were isolated guided by their bioactivity toward the target enzyme HLE, MALDITOF, and molecular biological analysis. The insulapeptolides A–H (38-45) selectively inhibited HLE with IC$_{50}$ 0.1, 0.1, 0.09, 0.08, 3.2, 1.6, 3.5, and 2.7 µM, respectively (Mehner et al., 2008).

Polypeptides From the Cyanobacteria Microcystis spp.

The new microviridins B (46) and C (47) (Figure 9) were also obtained from Microcystis aeruginosa. These compounds potentially inhibited elastase activity with IC$_{50}$ 2.6 and 4.8 µM, respectively (Okino et al., 1995).

The aqueous extract of Microcystis sp. produced several polypeptides including micropeptins MM836 (48), MM932 (49), MM978 (50), anabaenopeptins MM823 (51), and
MM850 (52) (Figure 10). These metabolites were purified using sephadex LH-20 and RP-ODS column. These compounds inhibited the elastase activity with IC$_{50}$ between 4.4 and 50.0 µM, with compound 49 displaying the most potential (IC$_{50}$ = 4.4 µM) (Zafrir-ilan and Carmeli, 2010) (Table 1). No Data is available on either mode of action or the cytotoxicity of compounds 48-52. However, comparison of the IC$_{50}$ values disclosed that the degree of binding of the micropeptins to the elastase catalytic pocket increases when residue-2 is comprised of tyrosine instead of phenylalanine. Anabaenopeptins are mild inhibitors of serine proteases as compared to the micropeptins, however, among anabaenopeptins, the higher binding affinity of 52 is attributed to an OMeArg in the ureido-bridge of 52, which is OMeGlu in 51.

Microcystis aeruginosa (IL-399) synthesized micropeptins HH978 (53), HH960 (54), and HH992 (55) (Figure 10). Compounds 53-55 inhibited elastase with IC$_{50}$ 17.6, 55.5, and 16.9 µM, respectively, but not thrombin and trypsin at a concentration of 45.5 µM, which showed their selectivity towards elastase enzyme. Comparison of the elastase inhibitory potential of 53 and 54 revealed the importance of the Ahp-6-OH group. However, in contrast, the comparison of the anti-elastase potential of compounds 53 and 55 revealed that the enzyme is liberal to the structural variation and also accepts the Mpc moiety (Lodin-Friedman and Carmeli, 2013). Another micropeptin, DR1006 (56) (Figure 10), has also been reported as a metabolite of Microcystis aeruginosa and inhibited elastase with an IC$_{50}$ 13.0 µM (Adiv et al., 2010). The SAR studies with other co-isolated compounds concluded that the elastase inhibitory activity of compound 56 can be attributed to the leucine moiety in the 5th position from the C-terminus. This conclusion is also consistent with the activity of other similar compounds (Adiv et al., 2010).

**Polypeptide From the Cyanobacterium Dichothrix utahensis**

Molassamide (57) (Figure 11), an analogue of dolastatin, is considered to be the first peptide separated from marine cyanobacterial assemblages of Dichothrix utahensis (from Brewer’s Bay, Virgin Islands and from the Molasses Reef, Florida). The structure of 57 was established through NMR spectroscopic techniques, while the absolute configuration at chiral centers was assigned through chiral HPLC analysis of the hydrolyzed products. Compound 57 exhibited potent...
FIGURE 10 | Structures of micropeptins 48-50 are with Ahp unit, 53-56 are also with Ahp unit, and the anabaenopeptins 51-52 are without Ahp unit. These micropeptins are depsipeptides. The anabaenopeptins are hexapeptides and cyclic through the cyclization of the C-terminal aa carboxyl to the ε-amine residue of the N-terminal D-lysine, while the α-amine of this lysine fraction is linked through an ureido-bridge to the side chain of another aa. All anabaenopeptins described to date from cyanobacteria, contain D-lysine, and have an L-absolute configuration for the other aa.
### TABLE 1 | Natural polypeptides having activity against elastase and their IC$_{50}$.

| Compound | Name | IC$_{50}$ against HNE/µM | IC$_{50}$ against PPE/µM | Reference |
|----------|------|--------------------------|--------------------------|-----------|
| Anti-elastase polypeptides of bacterial origin | Lyngbyastatin 4 | 0.049 | 0.03 | (Matthew et al., 2007; Salvador et al., 2013) |
| | Lyngbyastatin 5 | 0.0032 | | (Taori et al., 2007; Salvador et al., 2013) |
| | Lyngbyastatin 6 | 0.0033 | | (Taori et al., 2007; Salvador et al., 2013) |
| | Lyngbyastatin 7 | 0.0023 | 0.0083 | (Taori et al., 2007; Salvador et al., 2013) |
| | Somamide B | 0.0095 | 0.0095 | (Taori et al., 2007; Salvador et al., 2013) |
| | Lyngbyastatin 8 | 0.123 | | (Kwan et al., 2009) |
| | Lyngbyastatin 9 | 0.210 | | (Kwan et al., 2009) |
| | Lyngbyastatin 10 | 0.120 | | (Kwan et al., 2009) |
| | Bouillomide A | 1.9 | | (Rubio et al., 2010) |
| | Bouillomide B | 1.9 | | (Rubio et al., 2010) |
| | Kempopeptin A | 0.3 | | (Taori et al., 2009) |
| | Tiglicamide A | 2.1 | | (Matthew et al., 2009a) |
| | Tiglicamide B | 6.9 | | (Matthew et al., 2009a) |
| | Tiglicamide C | 7.3 | | (Matthew et al., 2009a) |
| | Largarimide A | 1.4 | | (Matthew et al., 2009a) |
| | Largarimide B | 0.5 | | (Matthew et al., 2009a) |
| | Largarimide C | 1.2 | | (Matthew et al., 2009a) |
| | Symplastin 5 | 0.068 | | (Salvador et al., 2013) |
| | Symplastin 6 | 0.069 | | (Salvador et al., 2013) |
| | Symplastin 7 | 0.077 | | (Salvador et al., 2013) |
| | Symplastin 8 | 0.041 | 0.043 | (Salvador et al., 2013) |
| | Symplastin 9 | 0.028 | 0.037 | (Salvador et al., 2013) |
| | Symplastin 10 | 0.021 | 0.044 | (Salvador et al., 2013) |
| | Stigonemapeptin | 0.3 | | (Kang et al., 2012) |
| | Oscillapeptin | 2.5 | | (Shin et al., 1995) |
| | Oscillapeptin A | 2.5 | | (Itou et al., 1999) |
| | Oscillapeptin B | 4.2 | | (Itou et al., 1999) |
| | Oscillapeptin D | 2.6 | | (Itou et al., 1999) |
| | Oscillapeptin E | 2.7 | | (Itou et al., 1999) |
| | Oscillapeptin G | 1.0 | | (Fujii et al., 2000) |
| | Oscillapeptilide 97-A | 6.9 | | (Fujii et al., 2000) |
| | Oscillapeptilide 97-B | 3.9 | | (Fujii et al., 2000) |
| | Microviridin I | 1.9 | | (Fujii et al., 2000) |
| | Microviridin G | 1.0 | | (Murakami et al., 1997) |
| | Microviridin H | 1.7 | | (Murakami et al., 1997) |
| | Nostopeptin A | 1.3 | | (Okino et al., 1997) |
| | Nostopeptin B | 1.2 | | (Okino et al., 1997) |
| | Insulapeptolide A | 0.1 | | (Mehner et al., 2008) |
| | Insulapeptolide B | 0.1 | | (Mehner et al., 2008) |
| | Insulapeptolide C | 0.09 | | (Mehner et al., 2008) |
| | Insulapeptolide D | 0.08 | | (Mehner et al., 2008) |
| | Insulapeptolide E | 3.2 | | (Mehner et al., 2008) |
| | Insulapeptolide F | 1.6 | | (Mehner et al., 2008) |
| | Insulapeptolide G | 3.5 | | (Mehner et al., 2008) |
| | Insulapeptolide H | 2.7 | | (Mehner et al., 2008) |
| | Microviridin C | 2.6 | | (Okino et al., 1995) |
| | Microviridin C | 4.8 | | (Okino et al., 1995) |
| | Micropeptin MM836 | 45.5 | | (Zafir-Ilan and Carmeli, 2010) |
| | Micropeptin MM932 | 4.4 | | (Zafir-Ilan and Carmeli, 2010) |
| | Micropeptin MM978 | 19.1 | | (Zafir-Ilan and Carmeli, 2010) |
| | Anabaenopeptin MM823 | 50.5 | | (Zafir-Ilan and Carmeli, 2010) |
| | anabaenopeptin MM850 | 14.3 | | (Zafir-Ilan and Carmeli, 2010) |
| | Micropeptin HH978 | 17.6 | | (Lodin-Friedman and Carmeli, 2013) |
| | Micropeptin HH960 | 55.5 | | (Lodin-Friedman and Carmeli, 2013) |
| | Micropeptin HH992 | 16.9 | | (Lodin-Friedman and Carmeli, 2013) |
| | micropceptin DR1006 | 13.0 | | (Adv et al., 2010) |
protease-inhibition activity, with IC\textsubscript{50} 0.03 and 0.23 µM against PPE and chymotrypsin, respectively (Gunasekera et al., 2010).

Another two cyclic depsipeptides, scyptolins A (58) and B (59) (Figure 12), were produced by \textit{Scytonema hofmanni} PCC 7110. Spectroscopic based analysis of their structures revealed that these metabolites have a unique side chain and an uncommon moiety 3′-chloro-N-methyl-Tyr. Compounds 58 and 59 consisted of the N-acylated peptide But\textsubscript{1}-Ala\textsubscript{2}-Thr\textsubscript{3}-Thr\textsubscript{4}-Leu\textsubscript{5}-Ahp\textsubscript{6}-Thr\textsubscript{7}-cmTyr\textsubscript{8}-Val\textsubscript{9}, to build a 19-membered ring through esterifying the Val\textsubscript{9} COOH with the Thr\textsubscript{4} OH. It is further explained that OH of the Thr\textsubscript{3} residue in compound 59 has another esterification bond with the N-butyroyl-Ala. Both the compounds 58 and 59 are reported to possess selective inhibition of PPE in vitro with IC\textsubscript{50} 1.6 and 1.4 µM, respectively (Matern et al., 2001; Matern et al., 2003a). The crystal structure of scyptolin A-PPE demonstrated that the elastase inhibitor occupies the prominent subsites S1 through S4 of the enzyme, and this rigid structure banned hydrolysis of the complex (Matern et al., 2003b). The above studies suggest that the type of aa present in between Thr and Ahp define the selective inhibition of serine proteases, which is attributed to the preferences of the different binding to specific pockets of the enzyme (Matern et al., 2003b). The scyptolins’ selectivity of elastase is likely regulated by the moiety in position 5, which corresponds to the P1 position of a substrate, which is leucine in the scyptolins (McDonough and Schofield, 2003).

Polypeptides From the Cyanobacterium \textit{Planktothrix rubescens}

Three planktopeptins, BL1125 (60), BL843 (61), and BL1061 (62) (Figure 13), were separated from the cyanobacterium \textit{Planktothrix rubescens}. The three compounds 60-62 inhibited the activity of elastase enzyme with IC\textsubscript{50} 0.096, 1.7, and 0.040 µM, respectively. It is stated that the flexible side chain moiety of compounds 60 and 62 is the factor for selectivity of elastase enzyme when compared with the activity for other enzymes (Grach-pogrebinsky et al., 2003).

Polypeptides of the Cyanobacterium \textit{Tychonema} sp.

The brunsvicamides A-C (63-65) (Figure 14) obtained from the cyanobacterium \textit{Tychonema} sp. were found to comprise six aa: five aa constitute a 19-membered ring skeleton, while the sixth aa is attached through urea moiety with the N- butyroyl-Ala. Both the compounds 58 and 59 are reported to possess selective inhibition of PPE in vitro with IC\textsubscript{50} 1.6 and 1.4 µM, respectively (Matern et al., 2001; Matern et al., 2003a). The crystal structure of scyptolin A-PPE demonstrated that the elastase inhibitor occupies the prominent subsites S1 through S4 of the enzyme, and this rigid structure banned hydrolysis of the complex (Matern et al., 2003b). The above studies suggest that the type of aa present in between Thr and Ahp define the selective inhibition of serine proteases, which is attributed to the preferences of the different binding to specific pockets of the enzyme (Matern et al., 2003b). The scyptolins’ selectivity of elastase is likely regulated by the moiety in position 5, which corresponds to the P1 position of a substrate, which is leucine in the scyptolins (McDonough and Schofield, 2003).
through modeling with the most active metabolite, brunsvicamide B (64). A reference co-crystal structure of scyptolin A and PPE was used, since the cyclic peptide core of scyptolin A has exactly the same number of aa and atoms as brunsvicamides. Based on the structural similarity, the investigators studied if the cyclic core of scyptolin A mimics the brunsvicamides A–C. Thus, the computational modeling suggested that brunsvicamides A–C might act by an inhibition mechanism which is similar to scyptolin A. The crystallographic data of the complex structure scyptolin A–elastase revealed that the active site of elastase was occupied by the macrocycle of scyptolin A in such a way as to prevent the access of water to make the cleavage difficult (Sisay et al., 2009).

**Polypeptides of the Bacterium *Streptomyces resistomicicus***

FR901277 (66) (Figure 15), a novel and unique bicyclic macrocyclic natural polypeptide, obtained from the bacterium filtrate *Streptomyces resistomicicus*, is a potent inhibitor of both PPE and HLE. Its unique bicyclic structure comprises of four...
normal aa [L-Orn(1), L-Thr(2), L-Phe(5), and L-Val(7)] and three unusual aa [dehydroxyThr(3), AA(4), and AA(6)], with a N-terminal of isopropyl carbonyl (Nakanishi et al., 2000b). FR901277 (66) inhibited both HLE and PPE with IC$_{50}$ of 0.2 and 0.3 µM, respectively (Nakanishi et al., 2000b). FR134043 (67) (Figure 15) is a disulfonated semisynthetic derivative of 66, which also has potent inhibitory activity against HLE with IC$_{50} = 0.04$ µM (Nakanishi et al., 2000a).

Polypeptides of the Bacterium *Flexibacter* sp. Q17897

The two cyclic-depsipeptides, designated YM-47141 (68) and YM-47142 (69) (Figure 15), were isolated from the fermented bacterium *Flexibacter* sp. Q17897. Both peptides are considered as the first natural compounds containing vicinal tricarbonyl functionality. They showed potent HLE inhibition with IC$_{50}$ values of 1.5 µM and 3.0 µM, respectively (Orita et al., 1995; Yasumuro et al., 1995). Their total synthesis has also been reported (Wasserman et al., 1999; Wasserman et al., 2000).

**ANTI-ELASTASE POLYPEPTIDES OF PLANT ORIGIN**

The peptide ixorapeptide II (70) (Figure 15) was discovered in the MeOH extract of *Ixora coccinea* (Rubiaceae). Compound 70 has been identified as a promising anti-inflammatory agent because it inhibited elastase release with IC$_{50}$ value 5.6 µM. The important feature is that compound 70 exhibited a 73-fold more potent inhibition of elastase release than the commercial drug phenylmethylsulfonyl fluoride (PMSF). It was, therefore, concluded that peptide 70 could be a promising anti-inflammatory drug lead with no cytotoxicity, and may be subjected to *in vivo* studies and clinical trials (Lee et al., 2010).

**ANTI-ELASTASE POLYPEPTIDES OF FUNGAL ORIGIN**

Besides cyanobacterial sources, epigenetic tools have also been utilized to get elastase inhibitor peptides from fungi. For example, supplementation of suberoylanilide hydroxamic acid (SAHA) to the medium of the fungus *Beauveria felina* resulted in the isolation of the cyclodepsipeptides of the isaridin type: desmethyilsaridin C2 (71), isaridin E (72), isaridin C2 (73), and roseocardin (74) (Figure 15). Their structural elucidation was proven through extensive spectroscopic measurements and chemical derivatization and compared with the literature data, however, the sequence of the amino acids were established due to EIMS experiments. Compounds 71-74 inhibited FMLP-induced elastase release in human neutrophils with IC$_{50}$ between 10.0 and 12.0 µM. SAR studies showed that the existence of allylic moiety in the co-isolated compounds destruxin A, resetoxin B, resulted in a decrease in anti-inflammatory activity. 71-74 exhibited anti-inflammatory activity without toxicity toward human neutrophils which were confirmed by the results of the measurement of cell viability by LDH which showed that these compounds hadn’t increased LDH release compared to the control (Chung et al., 2013).

The peptides AFUEI and AFLEI were isolated from *Aspergillus fumigatus* and *A. flavus*, respectively. They have an identical aa sequence. AFUEI is composed of 68 aa residues, and it was predicted as a signal peptide. AFUEI has a promising...
elastase inhibition which is more potent than the other elastase inhibitors in clinical trials (Sakuma et al., 2013).

ANTI-ELASTASE POLYPEPTIDES OF ANIMAL ORIGIN

Serine protease inhibitors (serpins) constitute a large protein class of native serine protease inhibitors with members spread over prokaryotes and eukaryotes (Zhang et al., 2017). Serpins have also been found in the venom of snakes, spiders, scorpions, cone snails, cnidarians, hymenopterans, and platypuses (Yuan et al., 2008). These inhibitors are mostly Kunitz-type toxins (the motif of the Kunitz-type toxins usually has a peptide chain of around 60 aa residues and is stabilized by three disulphide bridges (Yuan et al., 2008)). However, extensive transcriptomic and proteomic analysis of the venoms of animals also led to the discovery of non-Kunitz inhibitors (Xu et al., 2014; Liu et al., 2015). In addition, other polypeptides as elastase inhibitors have also been found in other animal sources. For example, elastin (skin-derived antileukoproteinase) was obtained from the horny layers of the human skin of patients with psoriasis where their skin was characterized by hyperproliferating keratinocytes, and an inflammatory infiltrate consisting partly of neutrophils migrating into the affected skin epidermis. Elafin potently inhibited HLE and PPE in a 1:1 molar ratio with equilibrium dissociation constants ($K_i$) of $6 \times 10^{-10}$ and $1 \times 10^{-9}$ M, respectively. The aa sequencing revealed that elafin consists of 57 aa. Elafin was reported to have a crucial role in preventing elastase-mediated tissue proteolysis, which was attributed to the high affinity and the apparent specificity for elastases (Wiedow et al., 1990).

The elastasin peptide, identified in goats, is a serpin related to human $\alpha_1$-anti-chymotrypsin. Elastasin was an inhibitor of neutrophil elastase ($k_{ass} = 1.5 \times 10^6$ M$^{-1}$ S$^{-1}$). The specific activity, resistance to oxidative and proteolytic inactivation, and the presence of a P1 leucine residue in elastasin, is unique among inhibitory serpins. This serpin seems to be the major elastase inhibitor in goat plasma, which is involved in the control of goat neutrophil elastase (Potempa et al., 1995).

Pserspin, a putative serpin from the thermophile Pyrobaculum neutrophilum, irreversibly inhibited elastase-like protease in a temperature range between 20 and 100°C and the inhibitory activity of pserspin increased with the temperature (Zhang et al., 2017).

AvKTI, comprising of 170 aa, is the first spider (Araneus ventricosus) serine protease inhibitor of Kunitz-type, obtained through extensive transcriptomic and proteomic analysis of the venom of A. ventricosus. The inhibitory activity of AvKTI against human neutrophil elastase was determined, and it was found to be more potent than other elastase inhibitors in clinical trials. AvKTI was shown to be a promising candidate for the development of new therapeutic agents for the treatment of inflammatory diseases.
from the body of the spider instead of its venom. Out of 170 aa, 19-aa comprise a signal peptide, 94-aa make pro-peptide, and a Kunitz domain consisting of 57-aa peptide that shows features matching to Kunitz-type inhibitors, including a P1 lysine site and six conserved cysteine residues; it inhibited HNE IC$_{50}$: 0.447 µM (Wan et al., 2013b).

AvCI is a spider (Araneus ventricosus) polypeptide, consisted of 86 aa, including a 16-aa signal peptide and a 70-aa mature peptide that displays a P1 lysine residue and eight conserved cysteine residues. AvCI potently inhibited HNE with IC$_{50}$ of 0.011 µM which was 1.65-fold more than its PPE inhibition (IC$_{50}$ = 0.019 µM) (Wan et al., 2013a).

Kim et al. reported the first bee-derived serine protease inhibitor, AcCI, which was obtained from the body and venom of Asiatic honeybee (Apis cerana) worker bees. AcCI was found to consist of 85-aa that includes a 20-aa signal peptide and a 65-aa mature peptide that displays a P1 site and ten cysteine residues. AcCI inhibited HNE (IC$_{50}$: 0.038 µM) which was a 1.8-fold stronger inhibition than that against PPE (IC$_{50}$: 0.07 µM) (Kim et al., 2013).

BmKPI is the Buthus martensi Kunitz-type protease inhibitor which was present in the venom gland of the scorpion B. martensi. It has a unique disulfide framework where it has a unique cysteine skeleton reticulated by four disulfide bridges (three disulfide bridges in many other Kunitztype proteins). The functionally expressed recombinant BmKPI peptide showed potent inhibition activity against PPE (KI 1.6 x 10$^{-7}$ M) and it is the first functionally characterized Kunitz-type elastase inhibitor derived from scorpion venom. The unique disulfide bridge Cys53–Cys61 had little effect on its elastase inhibition as shown by cysteine mutagenesis experiment (Chen et al., 2013).

Bungaruskinunin is a novel serine protease inhibitor and was isolated from the venom of Bungarus fasciatus. The predicted precursor is composed of 83 aa residues and it has a moderate inhibitory activity against elastase (KI of 6.9 x 10$^{-4}$ M) (Lu et al., 2008).

**DISCUSSION**

Inhibition of elastase enzyme is an important strategy for the alleviation of different inflammatory ailments and the discovery of new elastase modulators is deemed to be significant for the development of potential therapeutics and pharmacological tools. Polypeptides are an important class of natural products, identified as potential inhibitors of elastase enzyme, and hence can be used as a scaffold for designing more selective and potent inhibitors of the enzyme. Marine organisms are increasingly a prolific source of bioactive and unusual structural compounds (Donia and Hamann, 2003; Elsebai et al., 2011b; Elsebai et al., 2011a; Elsebai et al., 2014; Elsebai et al., 2016) and the cyanobacteria of marine origin have been recognized as a fruitful arsenal of polypeptides possessing promising inhibitory activity against serine proteases. Several cyclic peptides and depsipeptides have recently been isolated from cyanobacteria, and they have an attractive molecular architecture with a constrained conformation.

Nearly all the aforementioned polypeptides are cyclic depsipeptides containing modified and unusual aa residues, such as the modified glutamic acid moiety, Ahp (3-amino-6-OH-2-piperidone). The Ahp-containing depsipeptides have the ability to inhibit serine proteases (such as elastase, chymotrypsin, and trypsin with different inhibition selectivity depending on the differences in their aa composition), and hence their ecological role is supposed to be as inhibitors of digestive enzymes and a chemical defense against crustacean predators. They exhibited significant anti-elastase activities even up to a nanomolar concentration, specially lyngbyastatin 4 (I) and its analogues such as lyngbyastatin 5-7 (2-4) and insulapeptolides C and D (37, 38).

The Ahp-bearing cyclic depsipeptides are a significant family, primarily due to their structural diversity, predominance, and potent protease-inhibitor activity. The role of such compounds in nature may be as digestive inhibitors in herbivores, feeding deterrents, and possibly regulators of the biosynthesis of coexisting secondary constituents (Salvador et al., 2013). Further SAR analysis of compounds 2-5 revealed that the Abu moiety plays a significant role in selective inhibition of elastase, and overall the cyclic structural core for 1-5 demonstrated a potent inhibitor prototype. The crystal structural data of the Abu-containing bicyclic inhibitor FR901277 (66) bound to PPE (Nakanishi et al., 2000b) established that the ethylidene functionality of Abu was stabilized by CH/π interaction (Salvador et al., 2013). It is therefore proposed that such an enzyme-inhibitor interaction may also exist in the case of monocyclic inhibitors 1-5. The complexity and molecular diversity of polypeptides are evident from the lines above, which might be responsible for their anti-inflammatory potential. Structural complexity and diversity, however, is not the only reason; an important additional feature is their selectivity and specificity based on their mechanisms of action.

The selectivity inhibition of Ahp-containing depsipeptides against elastase is increased when the Abu residue is neighbor to the Ahp residue as compared to other serine proteases. The reason for this varying activity could be the different binding preferences to the specificity pocket of the enzyme (Kuo et al., 2013). Previously, several reports have been published on the related Ahp-containing protease inhibitors of cyanobacterial origin, and are assumed to be enzyme-substrate mimics (Itou et al., 1999; Yamaki et al., 2005). This assumption leads to the conclusion that polypeptides also inhibit elastase in a competitive way using Michaelis–Menten kinetics, since the residue between Thr and Ahp units presumably defines the specificity toward specific serine proteases (Matern et al., 2003b; Yamaki et al., 2005; Salvador et al., 2013). Through identification of the IFR (interface forming residues) for serine proteases in silico docked to different inhibitors, it was concluded that the serine proteases interfaces prefer polar residues (with some exceptions) (Ribeiro et al., 2010).

Based on the current review, cyanobacteria are an abundant source of bioactive peptides and depsipeptides since they have been identified to produce a variety of similar anti-inflammatory polypeptides (Tan, 2010). It is, therefore, concluded that cyanobacteria could be one of the most promising and
potential targets for drug discovery and development (Burja et al., 2001). Literature reports revealed that the cyanobacterial secondary metabolites are remarkably diverse in their structural features, with modified peptide–polyketide hybrids. They are biosynthesized by either nonribosomal polypeptide synthetases (NRPS), mixed polyketide synthase–NRPS pathways (Tan, 2007), or ribosomally (McIntosh et al., 2009).

Animal biological fluids and venoms are promising for their potential, and yet remain underestimated sources for biological agents against elastases. Animal venoms will potentiate the development of natural therapeutic and diagnostic drugs for human diseases that target different proteases.

Despite the fact that during the recent past, the synthetic libraries were being considered for the development of new lead drugs, we still believe that nature will continue to be a significant inspiring source of new anti-inflammatory drugs.

It is worth mentioning that the activity of the aforementioned polypeptides is lacking in vivo evaluation, however, the above-mentioned in vitro results may lead to in vivo studies of these molecules. Since most of these polypeptides are complex structures, which are difficult to synthesize chemically, to study their biological properties also requires screening of natural molecules. However, this is not the case for small molecules acting as elastase inhibitors (Saleem et al., 2018). Therefore, the in vitro elastase inhibitory studies of the natural polypeptides embodied in this document may provide a milestone for drug development and design.

**AUTHOR CONTRIBUTIONS**

SA outlined the article and collection of data. MS: collection of data, redrawing the structures, and proof-reading. NR and YL: proof-reading. RD, AB, AN, and DA: proofreading and partial contribution for publication fees. ME: collection of data, redrawing the chemical structures, and proof-reading.

**ACKNOWLEDGMENTS**

MS is highly obliged to Mrs. Topsy Smelle for providing several articles related to this review.

**REFERENCES**

Adiv, S., Aharonv-nadborny, R., and Carmeli, S. (2010). Micropeptins from Microcystis aeruginosa collected in Dalton reservoir, Israel. *Tetrahedron* 66, 7429–7436. doi: 10.1016/j.tet.2010.06.071

Barnes, P. J., and Stockley, R. A. (2005). COPD: Current therapeutic interventions and future approaches. *Eur. Respir. J.* 25, 1084–1106. doi: 10.1183/09031936.05.00139104

Burja, A. M., Banaigs, B., Abou-mansour, E., Grant, J., and Wright, P. C. (2001). Marine cyanobacteria–A prolific source of natural products. *Tetrahedron Lett.* 42, 9347–9377. doi: 10.1016/S0040-4020(01)00931-0

Chen, Z., Cao, Z., Li, W., and Wu, Y. (2013). Cloning and characterization of a novel Kunitz-type inhibitor from scorpion with unique cysteine framework. *Toxicol* 72, 5–10. doi: 10.1016/j.toxicol.2013.05.022

Chung, Y.-M., El-Shazly, M., Chuang, D.-W., Hwang, T.-L., Asai, T., Oshima, Y., et al. (2013). Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor, Induces the Production of Anti-inflammatory Cycloedepsipeptides from Beauveria felina. *J. Nat. Prod.* 76, 1260–1266. doi: 10.1021/np400143j

Croccetti, L., Quinn, M. T., Schepetkin, I. A., and Giovannini, M. P. (2019). A patenting perspective on human neutrophil elastase (HNE) inhibitors, (2014-2018) and their therapeutic applications. *Expert Opin. Ther. Pat.* 29, 555–578. doi: 10.1080/13543776.2019.1630379

De, M. V., Silva, P. L., and Macedo, P. R. (2016). Animal Models of Chronic Obstructive Pulmonary Disease Exacerbations: A Review of the Current Status Abstract. *J. Biomed. Sci.* 1–14. doi: 10.4172/2254-609X.100022

Di, L. (2014). Strategic approaches to optimizing peptide ADME properties. *AAPS J.* 17, 134–143. doi: 10.1016/s1224-9148(13)60073-8

Dittrich, A. S., Kuhbandner, I., Gehrig, S., Rickert-Zacharias, V., Twigg, M., Wege, S., et al. (2018). Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis. *Eur. Respir. J.* 51 (3), 1701910. doi: 10.1183/13993003.01910-2017

Donia, M., and Hamann, M. T. (2003). Marine natural products and their potential applications as anti-infective agents. *Lancet Infect. Dis.* 3, 338–348. doi: 10.1016/S1473-3099(03)00655-8

Elsebai, M. F., Kehraus, S., Mohamed, I. E., Schnakenburg, G., Sasse, F., et al. (2011b). HLE-Inhibitory Alkaloids with a Polyketide Skeleton from the Marine-Derived Fungus Coniothyrium cereale. *J. Nat. Prod.* 74, 2282–2285. doi: 10.1021/np2004227

Elsebai, M. F., Nazir, M., Kehraus, S., Egerova, E., Isset, K. N., Marcourt, L., et al. (2012). Polyketide skeletos from the marine alga-derived fungus coniothyrium cereale. *Eur. J. Org. Chem.* 2012 (31), 6197–6203. doi: 10.1002/ejoc.201200700

Elsebai, M. F., Saleem, M., Tejevisi, M. V., Kajula, M., Mattila, S., Mehiri, M., et al. (2014). Fungal phenalenones: chemistry, biology, biosynthesis and phylogeny. *Nat. Prod. Rep.* 31, 628–645. doi: 10.1039/c3np70088g

Elsebai, M. F., Ghabbour, H. A., and Mehiri, M. (2016). Unusual Nitrogenous Phenalenone Derivatives from the Marine-Derived Fungus Coniothyrium cereale. *Molecules* 21, 1–13. doi: 10.3390/molecules21020178

Fujii, K., Sivonen, K., Naganawa, E., and Harada, K. (2000). Non-toxic peptides from toxic cyanobacteria, Oscillatoria agaridii. *Tetrahedron* 56, 723–733. doi: 10.1016/S0040-4020(99)01017-0

Giacalone, V. D., Margaroli, C., Mall, M. A., and Tirouvanziam, R. (2020). Neutrophil Adaptations upon Recruitment to the Lung: New Concepts and Implications for Homeostasis and Disease. *Int. J. Mol. Sci.* 21, 851. doi: 10.3390/ijms21030851

Grach-pogrebinsky, O., Sedmak, B., and Carmeli, S. (2003). Protease inhibitors from a Slovenian Lake Bled toxic waterbloom of the cyanobacterium Planktothrix rubescens. *Tetrahedron* 59, 8329–8336. doi: 10.1016/j.tet.2003.09.006

Gunasekera, S. P., Miller, M. W., Kwan, J. C., Luesch, H., Paul, V. J., and Gaines, V. (2010). Molassamide, a Depsipeptide Serine Protease Inhibitor from the Marine Cyanobacterium. *J. Nat. Prod.* 73, 459–462. doi: 10.1021/np900603f

Hilhorst, M., van Paassen, P., Tervaert, J. W. C., and Registry, L. R. (2015). Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. *J. Am. Soc. Nephrol.* 26, 2314–2327. doi: 10.1681/ASN.2014090903

Horwitz, M., Benson, K. F., Person, R. E., Aprikyan, A. G., and Dale, D. C. (1999). Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. *Nat. Genet.* 23, 433–436. doi: 10.1038/70544

Ito, Y., Ishida, K., Shin, H. I., and Murakami, M. (1999). Oscillapeptins A to F, Serine Protease Inhibitors from the Three Strains of Oscillatoria agaridii. *Tetrahedron* 55, 6871–6882. doi: 10.1016/S0040-4020(99)00341-5
Kang, H., Krunic, A., and Orjala, J. (2012). Stigonemapeptin, an Ahp-Containing Depsipeptide with Elastase Inhibitory Activity from the Bloom-Forming Freshwater Cyanobacterium Stigonema sp. J. Nat. Prod. 75, 807–811. doi: 10.1021/np300150h

Khan, M. A., Ali, Z. S., Sweezy, N., Grasemann, H., and Palaniyar, N. (2019). Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. Genes (Basel). 10, E183. doi: 10.3390/genes10030183

Kim, B. Y., Lee, K. S., Wan, H., Zou, F. M., Choi, Y. S., Yoon, H. J., et al. (2013). Anti-elastolytic activity of a honeybee (Apis cerana) chymotrypsin inhibitor. Biochem. Biophys. Res. Commun. 430, 144–149. doi: 10.1016/j.bbrc.2012.11.056

Kuo, W. L., Chung, C. Y., Hwang, T. L., and Chen, J. J. (2013). Biphenyl-type neolignans from Magnolia officinalis and their anti-inflammatory activities. Phytochemistry 85, 153–160. doi: 10.1016/j.phytochem.2012.08.014

Kwan, J. C., Taori, K., Paul, V. J., and Luesch, H. (2009). Lyngbyastatins 8–10, Elastase Inhibitors with Cyclic Depsipeptide Scaffolds Isolated from the Marine Cyanobacterium Lyngbya semiplena. Mar. Drugs 7, 528–538. doi: 10.3390/md7040528

Lee, C., Liao, Y., Hwang, T. W., and Chang, F. (2010). Ixorapeptide I and ixorapeptide II, bioactive peptides isolated from Ixora coccinea. Bioorg. Med. Chem. Lett. 20, 7354–7357. doi: 10.1016/j.bmcl.2010.10.058

Liu, H., Chen, J., Wang, X., Yan, S., Xu, Y., San, M., et al. (2015). Functional Neurotrophins, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. J. Pept. Res. 55, 120–128. doi: 10.1034/j.1399-3011.2000.00165.x

Luo, D., and Luesch, H. (2020). Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis. ACS Med. Chem. Lett. 11, 419–425. doi: 10.1021/acsmedchemlett.9b00473

Luo, D., and Luesch, H. (2012). Stigonemapeptin, an Ahp-Containing Elastolytic Activity of a Honeybee (Apis cerana) Chymotrypsin Inhibitor. Biochem. Biophys. Res. Commun. 430, 144–149. doi: 10.1016/j.bbrc.2012.11.056

Ma, J., Yang, H., Yu, H., Gao, W., Lai, R., Liu, J., et al. (2008). A novel serine protease inhibitor from Bungarus fasciatus venom. Peptides 29, 369–374. doi: 10.1016/j.peptides.2007.11.013

Matthew, S., Paul, V. J., and Luesch, H. (2009a). Largamides A–C, tiglic acid-cation of FR134043, a novel macrocyclic inhibitor of elastases, at 1.6 Å Resolution. J. Mol. Biol. 390, 1430–1434. doi: 10.1016/j.chembiol.2009.10.062

Okino, T., Matsuoka, H., Murakami, M., and Yamaguchi, K. (1995). New Microviridins, Elastase Inhibitors from the Blue-Green Alga Microcystis-Aeruginosa. Tetrahedron 51, 10679–10686. doi: 10.1016/0040-4020(95)00643-O

Okino, T., Qu, S., Matsuoka, H., Murakami, M., and Yamaguchi, K. (1997). Nostopeptins A and B, Elastase Inhibitors from the Cyanobacterium Nostoc minutum. J. Nat. Prod. 60, 158–161. doi: 10.1021/np960649a

Orita, M., Yasumuro, K., Kokubo, K., Shimizu, M., Abe, K., Tokunaga, T., et al. (1995). YM-47141 and YM-47142, new elastase inhibitors produced by Flexibacter sp. Q17897. II. Structure elucidation. J. Antibiot. (Tokyo). 48, 1430–1434. doi: 10.7164/antibiotics.48.1430

Potempa, I., Engbladt, J. L., and Travist, J. (1995). The primary elastase inhibitor (elastasin) and trypsin inhibitor (contrasin) in the goat are serpins related to human α1-antichymotrypsin. Biochem. J. 306, 191–197. doi: 10.1042/bj0360191

Ribeiro, C., Towaga, R. C., Neschich, I. A. P., Mazoni, I., Mancini, A. L., Minardi, R. C., et al. (2010). Analysis of binding properties and specificity through identification of the interface forming residues (IFR) for serine proteases in silico docked to different inhibitors. BMC Struct. Biol. 10, 36. doi: 10.1186/1423-0001-10-36

Rubio, B. K., Parrish, S. M., Yoshida, V., Schupp, P. J., Schils, T., and Williams, P. G. (2010). Depsipeptides from a Guamanian marine cyanobacterium, Lyngbya boulloni, with selective inhibition of serine proteases. Tetrahedron Lett. 51, 6718–6721. doi: 10.1016/j.tetlet.2010.10.062

Sakuma, M., Imada, K., Okumura, Y., Uchiya, K., Yamashita, N., Ogawa, K., et al. (2013). X-ray structure analysis and characterization of AFUEI, an elastase inhibitor from Aspergillus fumigatus. J. Biol. Chem. 288, 17451–17459. doi: 10.1074/jbc.M112.433987

Saleem, M., Nazir, M., Hussain, H., and Tousif, M. I. (2018). Natural Phenolics as Inhibitors of the Human Neutrophil Elastase (HNE) Release: An Overview of Natural Anti-inflammatory Discoveries during Recent Years. Antimicrob. Agents Med. Chem. 17, 70–94. doi: 10.2174/1871253017666801090104940

Sakuma, M., Imada, K., Okumura, Y., Uchiya, K., Yamashita, N., Ogawa, K., et al. (2013). Potent Elastase Inhibitors from Cyanobacteria: Structural Basis and Mechanisms Mediating Cytoprotective and Anti-Inflammatory Effects in Bronchial Epithelial Cells. J. Med. Chem. 56, 1276–1290. doi: 10.1021/jm3017305

Shin, H. J., Murakami, M., Matsuda, H., Ishida, K., and Yamaguchi, K. (1995). Oscillapeptin, an Elastase and Chymotrypsin Inhibitor from the Cyanobacterium Oscillatoria agardhii (NIES-204). Tetrahedron Lett. 36, 5235–5238. doi: 10.1016/0040-0007(93)00301-L

Sisay, M. T., Hautmann, S., Mehner, C., König, G. M., Bajorath, J., and Gütschow, M. (2009). Inhibition of Human Leukocyte Elastase by Brunsvicamides A–C: Cyanobacterial Cyclic Peptides. ChemMedChem 4, 1425–1429. doi: 10.1002/cmdc.200900139

Tan, L. T. (2007). Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 68, 954–979. doi: 10.1016/j.phytochem.2007.01.012

Tan, L. T. (2010). Filamentous tropical marine cyanobacteria: A rich source of natural products for anticancer drug discovery. J. Appl. Phycol. 22, 659–676. doi: 10.1007/s10811-010-9506-x

Taori, K., Matthew, S., Roca, J. R., Paul, V. J., and Luesch, H. (2007). Lyngbyastatins 5–7, Potent Elastase Inhibitors from Florida Marine Cyanobacteria, Lyngbya spp. J. Nat. Prod. 70, 1593–1600. doi: 10.1021/ np0702436

Taori, K., Paul, V. J., Luesch, H., and April, R. V. (2008). Kemptopetins A and B, Serine Protease Inhibitors with Different Selectivity Profiles from a Marine
Cyanobacterium, Lyngbya sp. *J. Nat. Prod.* 71, 1625–1629. doi: 10.1021/np0002172

Thomas, M. P., Whangbo, J., McCrossan, G., Deutsch, A. J., Martinod, K., Walch, M., et al. (2014). Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins. *J. Immunol.* 192, 5390–5397. doi: 10.4099/jimmunol.1303296

Thulborn, S. J., Mistry, V., Brightling, C. E., Moffitt, K. L., Ribeiro, D., and Bafadhel, M. (2019). Neutrophil elastase as a biomarker for bacterial infection in COPD. *Respir. Res.* 20, 170. doi: 10.1186/s12931-019-1145-4

Tsai, Y.-F., Yu, H.-P., Chang, W.-Y., Liu, F.-C., Huang, Z.-C., and Hwang, T.-L. (2015). Sirtinol inhibits neutrophil elastase activity and attenuates lipopolysaccharide-mediated acute lung injury in mice. *Sci. Rep.* 5, 1–10. doi: 10.1038/srep08347

Wagner, C. J., Schultz, C., and Mall, M. A. (2016). Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease. *Mol. Cell. Pediatr.* 3, 25. doi: 10.1186/s40348-016-0053-7

Wan, H., Lee, K. S., Kim, B. Y., Yuan, M., Zhan, S., You, H., et al. (2013a). A spider (Araneus ventricosus) chymotrypsin inhibitor that acts as an elastase inhibitor and a microbial serine protease inhibitor. *Comp. Biochem. Physiol. Part B* 165, 36–41. doi: 10.1016/j.cbpb.2013.03.004

Wan, H., Lee, K. S., Kim, B. Y., Zou, F. M., Yoon, H. J., Je, Y. H., et al. (2013b). A Spider-Derived Kunitz-Type Serine Protease Inhibitor That Acts as a Plasmin Inhibitor and an Elastase Inhibitor. *PloS One* 8, 1–8. doi: 10.1371/journal.pone.0053343

Wasserman, H. H., Chen, J., Xia, M., Y. U., and Box, P. O. (1999). Total Syntheses of Depsipeptide Elastase Inhibitors YM-47141 and YM-47142 with use of Ylide Protection and Coupling Methods. *Syntheses of Depsipeptide Elastase Inhibitors YM-47141 and YM-47142 with* Helv. Chim. Acta 83, 2607–2616. doi: 10.1002/1522-2675(20000906)83:9<2607::AID-HLCA2607>3.0.CO;2-B

Wiedow, O., Schröder, J.-M., Gregory, H., Young, J. A., and Christophers, E. (1990). Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. *J. Biol. Chem.* 265, 14791–14795.

Xu, X., Duan, Z., Di, Z., He, Y., Li, J., Li, Z., et al. (2014). Proteomic analysis of the venom from the scorpion Mesobuthus martensi. *J. Proteomics* 106, 162–180. doi: 10.1016/j.jprot.2014.04.032

Yamaki, H., Sitachitta, N., Sano, T., and Kaya, K. (2005). Two New Chymotrypsin Inhibitors Isolated from the Cyanobacterium Microcystis aeruginosa NIES-88. *J. Nat. Prod.* 68, 14–18. doi: 10.1021/np040136l

Yasumuro, K., Suzuki, Y., Shibazaki, M., and Teramura, K. (1995). YM-47141 and 47142, new elastase inhibitors produced by Flexibacter sp. Q17897. *I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J. Antibiot. (Tokyo).* 48, 1425–1429. doi: 10.7164/antibiotics.48.1425

Yuan, C.-H., He, Q.-Y., Peng, K., Diao, J.-B., Jiang, L.-P., Tang, X., et al. (2008). Discovery of a distinct superfamily of Kunitz-type toxin (KTT) from tarantulas. *PloS One* 3, e3414. doi: 10.1371/journal.pone.0003414

Zafir-Ilan, E., and Carmeli, S. (2010). Eight novel serine proteases inhibitors from a water bloom of the cyanobacterium. *Tetrahedron* 66, 9194–9202. doi: 10.1016/j.tet.2010.09.067

Zeiher, B. G., Artigas, A., Vincent, J.-L., Dmitrienko, A., Jackson, K., Thompson, B. T., et al. (2004). Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. *Crit. Care Med.* 32, 1695–1702. doi: 10.1097/01.CCM.0000013333.48386.85

Zhang, H., Fei, R., Xue, B., Yu, S., Zhang, Z., Zhong, S., et al. (2017). Pnserpin: A Novel Serine Protease Inhibitor from Extremeophile Pyrococcus neutrophilum. *Int. J. Mol. Sci.* 18, 113. doi: 10.3390/ijms18010113

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Ahmad, Saleem, Riaz, Lee, Diri, Noor, Almasri, Bagalagel and Elsevier*. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.